It has become an axiom that the American pharmaceutical market, for all its innovation, is fundamentally broken when it comes to affordability. The latest case in point: the spectacular success of generic semaglutide in Canada, which has laid bare the grotesque pricing failures south of the border. Meanwhile, Britain’s NHS is being held up as a model of fiscal sanity. For the City, this is yet another lesson in the consequences of regulatory capture and the perverse incentives of a system that celebrates innovation but ignores the bottom line.
Let’s start with the numbers. In Canada, a month’s supply of generic semaglutide now costs roughly CAD $100. In the United States, the same drug, marketed as Ozempic by Novo Nordisk, can set you back over $900. That’s a nine-fold premium for a product that differs only in packaging and patent protection. The generic entry in Canada has been a triumph of regulatory pragmatism, leveraging international reference pricing and a willingness to negotiate. The US, by contrast, remains tethered to a Byzantine system of patents, rebates, and middlemen that inflates costs for patients and taxpayers alike.
For investors, the implications are clear. The pricing power of Big Pharma, once seen as invincible, is eroding. The market capitalisation of companies like Novo Nordisk has soared on the back of blockbuster drugs, but the Canadian example shows that generic competition can slash revenues in a flash. The US market, which accounts for the lion’s share of global profits, is now a ticking time bomb. Should Congress ever muster the political will to allow Medicare to negotiate prices seriously, or to fast-track generic approvals, the profit margins of the industry could collapse. The City’s analysts are already revising their models, factoring in a higher probability of price regulation in the next decade.
But the story doesn’t end with Canada. The UK’s NHS has long been the bane of pharmaceutical executives, using its single-payer muscle to drive hard bargains. The result? The NHS pays a fraction of US list prices for many drugs. The recent success of generic semaglutide in Canada has emboldened advocates of the British system. They argue that the UK model, which combines cost-effectiveness assessments with a willingness to say no, is the only sustainable way to manage healthcare spending. For a fiscal hawk, this is music to the ears. Government budgets are finite, and the notion that taxpayers should subsidise excessive drug company profits is madness.
The contrast with the US is stark. While the American system relies on private insurance and out-of-pocket payments, it has created a sprawling ecosystem of pharmacy benefit managers, rebate aggregators, and specialty pharmacies. Each layer adds cost with no corresponding value. The Canadian generic launch has shown that a simpler, more transparent approach can deliver results. The only losers are the shareholders of companies that have grown fat on US price discrimination.
Yet, we must temper our enthusiasm with a dose of realism. The UK’s NHS may be efficient at negotiating, but it faces its own demographic and fiscal challenges. An ageing population and rising chronic disease rates will put pressure on budgets, regardless of how cleverly they negotiate. Moreover, the City knows that the pharmaceutical industry is not a charity. If profits are squeezed too far, investment in R&D will dry up. The trick is to find a balance that rewards genuine innovation while punishing rent-seeking.
In the end, the Canadian generic Ozempic story is a parable of market failure and regulatory success. It reminds us that markets without proper oversight will always find ways to extract rents. The US model, with its ideological aversion to price controls, has created a dangerous dependence on high drug prices. The UK and Canada offer alternatives that are not perfect but are demonstrably more equitable. For investors, the message is to diversify away from pure-play US pharma and look to insurers and healthcare providers that benefit from lower drug costs. The bottom line, as always, is about fiscal discipline and common sense.
Will the US learn from this? I wouldn’t bet my portfolio on it. But the market is already voting with its feet, and capital flight from overvalued drug stocks has begun. The era of $900 drugs may be drawing to a close, and that is good news for everyone except the shareholders who ignored the warning signs.
